S B Patil, M Tamirat, K Khazhidinov, E Ardizzoni, M Atger, A Austin, E Baudin, M Bekhit, S Bektasov, E Berikova, M Bonnet, R Caboclo, M Chaudhry, V Chavan, S Cloez, J Coit, S Coutisson, Z Dakenova, B C De Jong, C Delifer, S Demaisons, J M Do, D Dos Santos Tozzi, V Ducher, G Ferlazzo, M Gouillou, U Khan, M Kunda, N Lachenal, A N LaHood, L Lecca, M Mazmanian, H McIlleron, M Moreau, M Moschioni, P Nahid, E Osso, L Oyewusi, S Panda, A Pâquet, P Thuong Huu, L Pichon, M L Rich, P Rupasinghe, N Salahuddin, E Sanchez Garavito, K J Seung, G E Velásquez, M Vallet, F Varaine, F J Yuya-Septoh, C D Mitnick, L Guglielmetti
BACKGROUND: Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens. To date, there has been no randomized, internally and concurrently controlled trial of a shorter, all-oral regimen comprising these newer and repurposed drugs sufficiently powered to produce results for pre-XDR TB patients...
November 30, 2023: Trials